Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?

Sepsis, newly defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, is the most common cause of death in ICUs and one of the principal causes of death worldwide. Although substantial progress has been made in the understanding of fundamental mechanisms...

Full description

Saved in:
Bibliographic Details
Main Authors: Jan Horák, Lukáš Nalos, Vendula Martínková, Jan Beneš, Milan Štengl, Martin Matějovič
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2017/7304121
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832565153374142464
author Jan Horák
Lukáš Nalos
Vendula Martínková
Jan Beneš
Milan Štengl
Martin Matějovič
author_facet Jan Horák
Lukáš Nalos
Vendula Martínková
Jan Beneš
Milan Štengl
Martin Matějovič
author_sort Jan Horák
collection DOAJ
description Sepsis, newly defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, is the most common cause of death in ICUs and one of the principal causes of death worldwide. Although substantial progress has been made in the understanding of fundamental mechanisms of sepsis, translation of these advances into clinically effective therapies has been disappointing. Given the extreme complexity of sepsis pathogenesis, the paradigm “one disease, one drug” is obviously flawed and combinations of multiple targets that involve early immunomodulation and cellular protection are needed. In this context, the immune-reprogramming properties of cell-based therapy using mesenchymal stem cells (MSC) represent an emerging therapeutic strategy in sepsis and associated organ dysfunction. This article provides an update of the current knowledge regarding MSC in preclinical models of sepsis and sepsis-induced acute kidney injury. Recommendations for further translational research in this field are discussed.
format Article
id doaj-art-3109297a5ca74d54b6c1006f923a1ab9
institution Kabale University
issn 1687-966X
1687-9678
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Stem Cells International
spelling doaj-art-3109297a5ca74d54b6c1006f923a1ab92025-02-03T01:09:05ZengWileyStem Cells International1687-966X1687-96782017-01-01201710.1155/2017/73041217304121Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?Jan Horák0Lukáš Nalos1Vendula Martínková2Jan Beneš3Milan Štengl4Martin Matějovič51st Medical Department, Faculty of Medicine in Pilsen, Charles University, Prague, Czech RepublicExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech RepublicExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech RepublicExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech RepublicExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech Republic1st Medical Department, Faculty of Medicine in Pilsen, Charles University, Prague, Czech RepublicSepsis, newly defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, is the most common cause of death in ICUs and one of the principal causes of death worldwide. Although substantial progress has been made in the understanding of fundamental mechanisms of sepsis, translation of these advances into clinically effective therapies has been disappointing. Given the extreme complexity of sepsis pathogenesis, the paradigm “one disease, one drug” is obviously flawed and combinations of multiple targets that involve early immunomodulation and cellular protection are needed. In this context, the immune-reprogramming properties of cell-based therapy using mesenchymal stem cells (MSC) represent an emerging therapeutic strategy in sepsis and associated organ dysfunction. This article provides an update of the current knowledge regarding MSC in preclinical models of sepsis and sepsis-induced acute kidney injury. Recommendations for further translational research in this field are discussed.http://dx.doi.org/10.1155/2017/7304121
spellingShingle Jan Horák
Lukáš Nalos
Vendula Martínková
Jan Beneš
Milan Štengl
Martin Matějovič
Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?
Stem Cells International
title Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?
title_full Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?
title_fullStr Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?
title_full_unstemmed Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?
title_short Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?
title_sort mesenchymal stem cells in sepsis and associated organ dysfunction a promising future or blind alley
url http://dx.doi.org/10.1155/2017/7304121
work_keys_str_mv AT janhorak mesenchymalstemcellsinsepsisandassociatedorgandysfunctionapromisingfutureorblindalley
AT lukasnalos mesenchymalstemcellsinsepsisandassociatedorgandysfunctionapromisingfutureorblindalley
AT vendulamartinkova mesenchymalstemcellsinsepsisandassociatedorgandysfunctionapromisingfutureorblindalley
AT janbenes mesenchymalstemcellsinsepsisandassociatedorgandysfunctionapromisingfutureorblindalley
AT milanstengl mesenchymalstemcellsinsepsisandassociatedorgandysfunctionapromisingfutureorblindalley
AT martinmatejovic mesenchymalstemcellsinsepsisandassociatedorgandysfunctionapromisingfutureorblindalley